CGTN
16.11.2020 10:11:09 CET | Business Wire | Press release
Two weeks after China unveiled a blueprint for its economic and social development for the next five years to 2025, Chinese leaders on Saturday laid out relatively specific plans and targets for the Yangtze River Economic Belt.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005494/en/
They included high-quality growth, green growth, opening-up as well as self-innovation.
These agendas were highlighted in a meeting in Nanjing, the capital city of Jiangsu Province, by Chinese President Xi Jinping, who just wrapped up inspection in the province.
Xi, also general secretary of the CPC Central Committee, went to Shanghai on November 12 to mark the 30th anniversary of Pudong's development and opening-up and later inspected Nantong and Yangzhou in Jiangsu.
This was Xi's first domestic inspection tour after the fifth plenary session of the 19th CPC Central Committee from October 26 to 29.
The key CPC meeting reviewed the 14th Five-Year Plan that takes high-quality growth as the goal for 2021-2025 and calls self-sufficiency in technology a strategic pillar for development.
It also said China will develop and urbanize regions, combine efforts to expand domestic demand with supply-side reform as well as widen its market to foreign capital.
Saturday's meeting decoded the grand development strategy for the first time for the vast region covering 11 provinces and municipalities.
At the meeting, Xi was briefed on the super-region's latest developments, and given advice and suggestions for future plans by four senior officials from the central government and chiefs from three provinces.
Xi said the super-region has made a remarkable contribution to China's recovery in the past months, pushing the country ahead of other major economies in pandemic recovery.
The plan to boost the Yangtze River Economic Belt must be consistent with the new development strategy, with an emphasis on a higher-quality growth, Xi said, adding it should be a role model for green growth, regional coordination, opening-up and self-innovation.
Xi said boosting the Yangtze River Economic Belt is of "strategic importance" as it covers 11 provinces and municipalities, from coastal regions Jiangsu and Shanghai to inland Sichuan and Chongqing.
Official data shows the super-region covers roughly one-fifth of China's land and has a population of 600 million, generating more than 40 percent of the country's GDP.
Environment vulnerability is the foremost concern for the sustainable growth of local economies along the river, Xi pointed out, asking officials to prioritize ecological restoration.
Stressing coordination, Xi said governments in the upper, middle and lower reaches of the river should overcome administrative barriers in restoring the ecology and improving mechanism monitoring, warning systems as well as disaster prevention and rescue procedures.
The Yangtze River Basin is now one of the most populated and developed regions in the world, but it also routinely suffers from flood in monsoon season.
This summer, the Yangtze River Basin saw the heaviest rainfall since 1961 and the worst flooding in decades.
According to the Ministry of Water Resources, some 219 people have died or gone missing in the floods and about 634.6 million people have been affected, causing economic losses of 178.96 billion yuan ($25.78 billion).
Speaking of the structural asymmetries of the Yangtze River Economic Belt, Xi said some labor-intensive companies can move their factories from coastal regions to inland areas, so as to stabilize domestic production and supply chain.
As the country's driving force, Xi said the super-region must build modernized industrial and supply chains that are more innovative, secure, reliable and valuable.
To reach the target, the region should invest more in innovation through setting up national and comprehensive innovative labs and giving more support to enterprises, he said.
He also renewed his pledge to open up market access, especially for inland regions, to foreign capital, and he asked officials to better integrate local economies into the Belt and Road Initiative so as to expand foreign investment and trade.
Chongqing and Chengdu, both along the Yangtze River Economic Belt, have already served as junctions of the Belt and Road Initiative.
They launched China-Europe freight train services in 2011 and 2013, respectively. Latest number showed that more than 10,000 freight trains had traveled between the two cities and Europe, accounting for over 40 percent of the total China-Europe train journeys.
Read the original article here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005494/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
